Outcomes of Trimodal Therapy for cT2-3 Urothelial Carcinoma in a Racially Diverse Population: A Single Institution Experience in the Bronx

BACKGROUND: Radical cystectomy (RC) is the historical 'gold standard' treatment for cT2-3 urothelial carcinoma (UC). However, recent evidence supports comparable outcomes of bladder preserving trimodal therapy (TMT) to RC in select patients. OBJECTIVE: To assess the oncologic outcomes of our institutional TMT experience. METHODS: We retrospectively identified all patients that received radiation therapy (RT) for cT2-3 UC from 2012 to 2018. Clinicopathologic data was then extracted from the patients' medical records. We included patients who underwent RT with or without concurrent chemotherapy for curative intent after diagnostic TURBT, with or without re-staging TURBT. Patient clinical (age, sex, race) and pathologic/disease characteristics of bladder cancer (stage, presence of hydronephrosis, concurrent carcinoma in-situ) were collected. Primary outcomes were: response to TMT (complete response [CR], partial response [PR], progression), recurrence-free, and overall survival. We also analyzed rates of salvage cystectomy and associated disease-specific outcomes. Response was based on the first surveillance imaging, cystoscopy, or TURBT after completion of TMT. RESULTS: 24 patients underwent TMT during the study period. 29.2% of patients were black/non-hispanic, 37.5% were latino/hispanic, and 20.8% were white/non-hispanic. 58.3% of patients were female. 19 (79.2%), 3 (12.5%), and 2 (8.3%) patients experienced CR, PR and progression after TMT, respectively. At a median follow-up of 22.4 months, 19 (79.2%) patients were recurrence-free, 3 were alive with disease (12.5%), and 2 expired from other causes (8.3%; 1 with and 1 without disease present). Overall, 22 (92.7%) patients were still alive at last follow-up. No clinical variables were significant predictors of CR to TMT. CONCLUSIONS: In concordance with prior reports, TMT offers excellent tumor response rates for patients seeking definitive therapy for cT2-3 UC. Extended follow-up is needed to assess the durability of response and long-term survival after TMT.